Embryonic Stem Cell-Derived Mesenchymal Stem Cells (MSCs) Have a Superior Neuroprotective Capacity Over Fetal MSCs in the Hypoxic-Ischemic Mouse Brain by Hawkins, Kate E et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1002/sctm.17-0260
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Hawkins, K. E., Corcelli, M., Dowding, K., Ranzoni, A. M., Vlahova, F., Hau, K-L., ... Guillot, P. V. (2018).
Embryonic Stem Cell-Derived Mesenchymal Stem Cells (MSCs) Have a Superior Neuroprotective Capacity Over
Fetal MSCs in the Hypoxic-Ischemic Mouse Brain. Stem cells translational medicine, 7.
https://doi.org/10.1002/sctm.17-0260
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Embryonic Stem Cell-Derived Mesenchymal Stem
Cells (MSCs) Have a Superior Neuroprotective
Capacity Over Fetal MSCs in the Hypoxic-Ischemic
Mouse Brain
KATE E. HAWKINS,
a
MICHELANGELO CORCELLI,
a
KATE DOWDING,
a
ANNA M. RANZONI,
a
FILIPA VLAHOVA,
a
KWAN-LEONG HAU,
a,b
AVINA HUNJAN,
a
DONALD PEEBLES,
a
PIERRE GRESSENS,
c
HENRIK HAGBERG,
c
PAOLO DE COPPI,
d
MARIYA HRISTOVA,
a
PASCALE V. GUILLOT
a
Key Words. Pluripotent stem cells • Mesenchymal stem cells • Fetal stem cells •
Cell transplantation • Embryonic stem cells • Induced pluripotent stem cells
ABSTRACT
Human mesenchymal stem cells (MSCs) have huge potential for regenerative medicine. In particu-
lar, the use of pluripotent stem cell-derived mesenchymal stem cells (PSC-MSCs) overcomes the
hurdle of replicative senescence associated with the in vitro expansion of primary cells and has
increased therapeutic beneﬁts in comparison to the use of various adult sources of MSCs in a wide
range of animal disease models. On the other hand, fetal MSCs exhibit faster growth kinetics and
possess longer telomeres and a wider differentiation potential than adult MSCs. Here, for the ﬁrst
time, we compare the therapeutic potential of PSC-MSCs (ES-MSCs from embryonic stem cells) to
fetal MSCs (AF-MSCs from the amniotic ﬂuid), demonstrating that ES-MSCs have a superior neuro-
protective potential over AF-MSCs in the mouse brain following hypoxia-ischemia. Further, we
demonstrate that nuclear factor (NF)-jB-stimulated interleukin (IL)-13 production contributes to
an increased in vitro anti-inﬂammatory potential of ES-MSC-conditioned medium (CM) over AF-
MSC-CM, thus suggesting a potential mechanism for this observation. Moreover, we show that
induced pluripotent stem cell-derived MSCs (iMSCs) exhibit many similarities to ES-MSCs, including
enhanced NF-jB signaling and IL-13 production in comparison to AF-MSCs. Future studies should
assess whether iMSCs also exhibit similar neuroprotective potential to ES-MSCs, thus presenting a
potential strategy to overcome the ethical issues associated with the use of embryonic stem cells
and providing a potential source of cells for autologous use against neonatal hypoxic-ischemic
encephalopathy in humans. STEM CELLS TRANSLATIONAL MEDICINE 2018;7:439–449
SIGNIFICANCE STATEMENT
Mesenchymal stem cells (MSCs) are currently under assessment in various clinical trials world-
wide. Their therapeutic potential is due largely to the factors they secrete. This study shows
that embryonic stem cell-derived MSCs have increased in vitro anti-inflammatory potential in
comparison to amniotic fluid-derived MSCs and that this translates to an increased in vivo neu-
roprotective capacity following hypoxic-ischemic injury of the mouse brain. These findings pro-
vide new insight into the molecular mechanisms underlying the therapeutic potential of MSCs.
By illuminating these molecular mechanisms, this study may have implications for improving
the efficiency of MSC therapies.
INTRODUCTION
Mesenchymal stromal/stem cells (MSCs) are mul-
tipotent cells found in various tissues throughout
development, where they contribute to the repair
and regeneration of these tissues. Human fetal
MSCs have been isolated from various fetal tis-
sues including ﬁrst trimester blood, liver, or
bone marrow (BM) [1–3], or from extraembryonic
tissues such as the placenta, umbilical cord or
amniotic ﬂuid [4, 5]. Due to their more primitive
phenotype, fetal MSCs present various advan-
tages over their adult counterparts such as longer
telomeres, active telomerase and a greater expan-
sion capacity [6]. MSCs, as deﬁned by their plastic
adherence, tri-lineage differentiation potential,
co-expression of the cell surface markers CD105,
CD90, and CD73 and absence of expression of
CD34 and CD45 [7], are currently under assess-
ment in numerous clinical trials worldwide
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targeting a range of disorders from myocardial infarction to stroke
[8]. However, the speciﬁc mechanisms by which they mediate
tissue regeneration in a range of disease contexts remain largely
elusive.
Increasing evidence suggests that the therapeutic potential of
MSCs should not be attributed only to their engraftment and dif-
ferentiation but also to the release of regenerative paracrine/
endocrine factors. These effects of MSCs were ﬁrst suggested
when, after injection, BM-MSCs exerted therapeutic effects on
the infarcted heart despite being detected largely in the lungs and
liver in various murine heart disease models [9, 10]. Furthermore,
MSC-conditioned medium (CM) has been shown to exert a thera-
peutic effect in animal models of cardiomyopathy [11] and MSC-
derived exosomes have been shown to ameliorate disorders of
the brain, kidney, and joints [12–15]. These studies are paving the
way for off-the-shelf cell-free therapies, which would have the
beneﬁts of being more well deﬁned and standardized than stem
cell treatments.
Standardization of cell-free therapies will require a thorough
understanding of the therapeutic factors that MSCs secrete. One
key class of molecules released by MSCs are anti-inﬂammatory
factors. These include interleukin 1 receptor agonist (IL-1ra) [16],
tumor necrosis factor (TNF)a-stimulated gene (TSG)6 [8, 17, 18],
prostaglandin (PG)E2 [16–19], indoleamine 2,3-dioxygenase (IDO)
[20–24], and IL-10 [19]. When in an inﬂammatory environment,
MSCs produce higher levels of these anti-inﬂammatory factors, a
phenomenon known as “licensing” [25–27]. Mechanistically, this
is likely due to activation of nuclear factor (NF)-jB signaling in
MSCs leading to transcription of downstream targets which
include anti-inﬂammatory cytokines. To support this idea, Dorron-
soro et al. [28] have shown that inhibition of NF-jB through
silencing of IjB kinase or the TNFa receptor TNFR1 abolishes the
capacity of MSCs to regulate Tcell proliferation and various groups
have shown that Toll-like receptor (TLR) engagement leads to
enhanced immunosuppressive properties in human BM-MSCs [18,
29, 30]. Moreover, Tomchuck et al. [31] have demonstrated that
NF-jB activation in MSCs leads to increased production of cyto-
kines, chemokines and related TLR gene products such as PGE2.
Human primary MSCs, especially those from aged donors,
have a limited proliferation capacity in vitro due to replicative
senescence [32–34] and higher passage MSCs are more likely to
trigger an innate immune attack upon transplantation into
humans [35]. In addition, cells derived from aged donors tend to
be more pro-inﬂammatory than those from younger donors
[36–38], thereby further restricting the clinical potential of
expanded human primary cells. To address these issues, various
groups have generated pluripotent stem cell-derived MSCs (PSC-
MSCs), of which there are two types, embryonic stem cell (ESC)-
derived MSCs (ES-MSCs) [39–41] and induced pluripotent stem
cell (iPSC)-derived MSCs (iMSCs). Pluripotent stem cells can be
expanded in vitro without undergoing senescence and PSC-MSCs
have been shown to have enhanced therapeutic potential com-
pared with other sources of MSCs in animal models of various dis-
eases including multiple sclerosis [42], cardiomyopathy [11],
pulmonary arterial hypertension [43], osteoarthritis [14], and limb
ischemia [44], potentially due to their “rejuvenated” phenotype
[45]. However, some studies report comparable [46–48] or even
decreased [45] immunosuppressive abilities of PSC-MSCs over
other sources of MSCs.
In this study, we compare for the ﬁrst time the neuroprotec-
tive potential of ES-MSCs and fetal amniotic ﬂuid-derived
(AF)-MSCs. We show that ES-MSCs have an increased neuropro-
tective capacity compared with AF-MSCs in a perinatal mouse
hypoxia-ischemia model. Further, we demonstrate in vitro that
increased NF-jB activation in ES-MSCs leads to elevated
interleukin (IL)-13 production, thus providing a potential mecha-
nism for the enhanced neuroprotective capacity of ES-MSCs over
AF-MSCs. Finally, we compare these two MSC lines to iMSCs,
showing that iMSCs also exhibit increased NF-jB activation, con-
comitant with elevated IL-13 production and increased anti-
inﬂammatory potential in comparison to AF-MSCs. Together, these
ﬁndings suggest that PSC-MSCs are a promising cell source for use
in therapeutic strategies targeting neonatal hypoxic-ischemic
encephalopathy (HIE) in humans.
MATERIALS AND METHODS
Ethics Statements
The healthy donors who provided the amniotic ﬂuid in this study
provided written informed consent in accordance with the Decla-
ration of Helsinki. The ethical approval given by the Research
Ethics Committees of Hammersmith & Queen Charlotte Hospitals
(2001/6234) was in compliance with U.K. national guidelines
(Review of the Guidance on the Research Use of Fetuses and Fetal
Material [1989], also known as the Polkinghome Guidelines Lon-
don: Her Majesty’s Stationary Ofﬁce, 1989: Cm762) for the collec-
tion of fetal tissue for research.
All animals were handled in strict accordance with good ani-
mal practice as deﬁned by the U.K. Home Ofﬁce Animal Welfare
Legislation (PPL 70/8784), The Institutional Licensing Committee
of Imperial College London and University College London (UCL)
and the Institutional Research Ethics Committee (Institute of Child
Health, UCL, London).
Cell Culture
Human AF-MSCs were isolated as previously described [4]. Unless
speciﬁed, cells were plated at 1 3 104 cells per cm2 in D10 (Dul-
becco’s modiﬁed Eagle’s medium supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, 50 IU/ml penicillin, and 50 mg/
ml streptomycin [all Sigma-Aldrich, Dorset, UK]) at 378C with 5%
CO2. Where indicated, 20 ng/ml TNFa (Sigma-Aldrich), 125 ng/ml
IL-13P (Santa Cruz Biotechnology, CA, USA) or an equal volume of
the appropriate vehicle was added to the cells in D10. The human
ESC line H1 (WiCell Research Institute, Madison, USA) was cul-
tured in feeder-free conditioned on Matrigel-coated plates in
mTESR (Stem Cell Technologies, Cambridge, UK).
Cell Proliferation Assay
5 3 104 cells per well were plated in twelve wells of a 12-well
plate and the cells were counted in triplicate 24, 48, 72, and 96
hours after plating.
iPSC Reprogramming of AF-MSCs
5 3 105 AF-MSCs were detached using TrypLE (Life Technologies,
Paisley, UK), centrifuged at 1,200 rpm for 5 minutes then electro-
porated as described previously [49] but without the pCXWB-
EBNA1 episomal plasmid. After transfection, cells were plated
onto one 0.1% gelatin (Sigma-Aldrich)-coated well of a 6-well
plate. Twenty-four hours post-transfection, cells were detached
and seeded into one 6 cm2 dish precoated with Matrigel (Scien-
tiﬁc Laboratory Supplies ltd, Nottingham, UK) in Essential 8
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medium (Life Technologies). The medium was then replenished
every 2 days until around day 20, when iPSC colonies were pas-
saged manually with a needle into a fresh Matrigel-coated well of
a 6-well plate in Essential 8 medium. Cells were passaged with
0.5 mM EDTA (Life Technologies) thereafter.
MSC Differentiation of Pluripotent Stem Cells
PSC-MSC differentiation was performed as described in Chen
et al. [50] with some modiﬁcations. Three iMSC and three ES-MSC
lines were generated. Brieﬂy, a conﬂuent T25 of ESCs or iPSCs was
treated with 10 mM SB431542 for 10 days before the cells were
passaged using Tryple Select (Life Technologies) at a 1:1 ratio into
StemMACS MSC expansion medium supplemented with CytoMix
according to the manufacturer’s instructions (both Miltenyi Bio-
tech, Bisley, UK). Cells were subsequently seeded at 2 3 104 cells
per cm2 at the ﬁrst passage, then 13 104 cells per cm2 thereafter
and analyzed around passage 6.
AF-MSC Transfection
Cells were electroporated as described above in electroporation
buffer containing 2 mg each of either pCMV-IKK2 or the pCMV-
FLAG control plasmid (both Addgene, Cambridge, UK).
Embryoid Body Formation
iPSCs were detached using EDTA and resuspended in Essential 8
medium containing 10 mM Y-27632 (Sigma-Aldrich) in bacterial
culture dishes (non-TC treated). The medium was replaced on day
2, then changed to D10 containing 20% FBS (D20) on days 4 and
6. On day 7, the embryoid bodies were plated onto 0.1% gelatin
(Sigma-Aldrich). The cells were fed every 2 days with D20 until
being ﬁxed with 4% PFA on day 14.
Lentiviral Production and Transduction
HEK 293T cells were plated at 80% conﬂuency in one well of a 6-
well plate. They were then transfected using poly polyethyleni-
mine precomplexed with 2.79 mg of the appropriate lentiviral vec-
tor along with 0.96 mg VSVg envelope plasmid and 1.79 mg
packaging plasmid (pCMVD8.74) in OptiMEM (Life Technologies)
for 3 hours prior to re-feeding. Culture medium was then har-
vested at 48 hours post-transfection and ﬁltered through a 0.45
mm PVDF ﬁlter (Elkay, Basingstoke, UK) on to one well of receiver
cells.
NF-jB Anti-Inflammatory Assay
HEK 293T cells were transduced with the pLNT-NF-jB-NLuc (NLuc)
and pLNT-SFFV-VLuc (VLuc) lentiviral plasmids as previously
described [49]. Reporter cells were then plated in triplicate in 24-
well plates. Twenty-four hours later, cells were activated with 20
ng/ml TNFa (Sigma-Aldrich). Twenty-four hours after activation,
12 ml CM from 6 wells of cells was concentrated in an Amicon
Ultra-15 3K NMWL ﬁlter (Millipore,Watford, UK) by centrifugation
at 4,000g for 30 minutes. The cells were then counted and the vol-
ume of medium added was adjusted according to cell number.
The appropriate volume of concentrated medium was added to
1.5 ml D10. 0.5 ml was then added to each well of reporter HEK
293T cells in triplicate. Twenty-four hours after the addition of CM
the medium was replaced with fresh D10 and luciferase assays
were performed following a further 24 hours.
RT-PCR
Total RNA was isolated and reverse transcribed to cDNA as previ-
ously described [49]. Reverse transcription (RT)-PCR was then per-
formed using 1 ml cDNA which was ampliﬁed for 30 cycles at 548C
using the appropriate primer pair (Table 1). Samples were sepa-
rated using a 1.5% agarose gel and visualized using a UV
transilluminator.
qRT-PCR
Total RNA was isolated and reverse transcribed to cDNA as previ-
ously described [49]. Triplicate samples containing the appropriate
primers (1 mM, Table 2) were analyzed by quantitative (q)RT-PCR
using SYBR Green PCR Master Mix (Life Technologies) according to
the manufacturer’s instructions.
Flow Cytometry
Cells were detached as described previously and washed in ﬂow
buffer (phosphate-buffered saline (PBS)1 1% BSA). Cells were
then centrifuged at 5,000g for 2 minutes before 1 3 105 cells
were resuspended in the appropriate primary antibody (anti-
CD105, anti-CD90, anti-CD73, anti-CD14 [All Miltenyi Biotec], anti-
CD29 [Abcam, Cambridge, UK], or anti-CD45 [BD Biosciences,
Wokingham, UK]) at its optimal dilution (1:10) in ﬂow buffer and
incubated for 1 hour at 48C. For unconjugated antibodies, cells
were then washed and resuspended in a 1:10 dilution of FITC-
conjugated donkey anti-mouse (Jackson ImmunoResearch labs,
PA, USA) for 30 minutes at 48C. Cells were then analyzed using a
Becton Dickinson FACScalibur ﬂow cytometer (BD biosciences)
using Cell Quest Pro and FlowJo software.
Luciferase Assays
The supernatant was collected from triplicate wells of cells at the
appropriate time points and 20 ml was transferred to 20 ml assay
buffer (25 mM Tris Phosphate [pH7.8] containing 1% BSA and 30%
glycerol, all Sigma-Aldrich) in a white-bottomed 96-well plate
(Corning, NY, USA) in technical triplicates. VLuc samples were
assayed detecting photonic emissions at 460 nm after addition of
5 nM vargulin (Gold Biotechnology, Olivette, USA) and NLuc pho-
tonic emissions at 454 nm after addition of 2 mM coelenterazine
(Gold Biotechnology) which had been incubated on ice for 45
minutes with 0.1 M KI and 10 mM EDTA (Sigma-Aldrich) using a
FLUOstar Optima luminometer (BMG Labtech, Ortenberg, Ger-
many). NLuc values were divided by VLuc values before the aver-
age fold change over control6 standard deviation was plotted
graphically.
p values were calculated using analysis of variance (One-way
ANOVA) followed by Bonferroni’s multiple comparison post hoc
test.
Immunofluorescent Cell Staining
Immunocytochemistry was performed as previously described
[49]. Brieﬂy, cells were washed with PBS and ﬁxed in situ using 4%
Table 1. Reverse transcription (RT)-PCR primers
Primer
target Forward sequence (50-30) Reverse sequence (50-30)
OCT4 CTGGAGAAGGAGAAGCTGGA AATAGAACCCCCAGGGTGAG
SOX2 GACCAGCTCGCAGACCTACAT TACCTCTTCCTCCCACTCCA
NANOG AGCCTCTACTCTTCCTACCACC TCCAAAGCAGCCTCCAAGTC
b-TUBULIN ACATCCAGGCTGGTCAGTGT CCCAGGTTCTAGATCCACCA
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PFA in PBS before being washed, permeabilized with 0.3% Triton
in PBS (if required) and blocked for 30 minutes in 2% BSA/0.05%
Triton in PBS. Cells were then incubated in the appropriate pri-
mary antibody overnight at 48C before being washed and incu-
bated with the appropriate secondary antibody for 1 hour at
room temperature in the dark. Finally, cells were washed, the
nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI) and
the cells were visualized on a Zeiss Axio Observer A1 ﬂuorescence
microscope. Additional antibodies used were anti-REX1, TRA-1–60,
and DNMT3B (all 1:200, Abcam) and an OCT4A-speciﬁc antibody
(Santa Cruz Biotechnology).
Enzyme-Linked Immunosorbent Assays
Cells were plated at 23 104 cells per cm2 in four wells of a 6-well
plate. Seventy-two hours after seeding, 8 ml CM was removed
and concentrated using an Amicon ultra-4 15ml 3K NMWL ﬁlter
by centrifugation at 4,000g for 40 minutes. 300 ll of D10 was
then added to the concentrated medium and 100 ml of this was
added per well of the enzyme-linked immunosorbent assay
(ELISA) plate. The mini ABTS ELISAs (Peprotech, London, UK) were
performed as per the manufacturer’s instructions.
Western Blot
Western blot was performed as described previously [49] with the
following antibodies: anti-IKK2 and anti-b-ACTIN (both 1:1,000,
Abcam).
Hypoxic-Ischemic Induction
All animal experiments and care protocols were carried out
according to the U.K. Animals (Scientiﬁc Procedures) Act 1986 and
approved by the Home Ofﬁce. The ARRIVE guidelines were fol-
lowed. All experiments involved C57/Bl6 mice obtained from
Charles River (Kent, U.K.). The surgical procedures were performed
as previously described [51]. Brieﬂy, male and female postnatal
day 7 (p7) mice were anesthetized with isoﬂuorane (5% induction
followed by 1.5% maintenance) before the left common carotid
artery was permanently ligated. The mice were then returned to
the dam for 2 hours before being exposed to 8% oxygen/92%
nitrogen at 368C for 1 hour. Immediately after hypoxic-ischemic
(HI) insult, 1 3 105 AF-MSCs or ES-MSCs were then injected in 2
ml PBS through a single contralateral injection taking approxi-
mately 60 seconds.
Tissue Sample Preparation
Animals were sacriﬁced at 48 hours post-injection by intraperito-
neal injection of pentobarbitane and perfused as described in
Hristova et al. [51] Brieﬂy, following sacriﬁce, animals were per-
fused with 30 ml 4% paraformaldehyde (PFA) in PBS. Brains were
then isolated, ﬁxed in 4% PFA for 1 hour at 48C and then cryopre-
served for 24 hours in phosphate-buffered sucrose solution before
being frozen in dry ice, cut on a cryostat into 40 mm sections and
stored at2808C until required for analysis.
Immunohistochemistry and Histological Analysis
Five cryosections from each brain (400 mm apart) were rehydrated
in H2O and then stained as previously described [51]. Infarct vol-
ume measurement was performed on cresyl violet-stained sec-
tions. These sections were imaged using a Zeiss Axiplan2 Axiocam
HRc camera and imported into Image J, which was then used to
determine the area of the following bilateral regions: cortex (CTX),
pyriform cortex (PYR), hippocampus (HPP), striatum (STR), thala-
mus (THAL), and external capsule (EC). The percentage tissue loss
in comparison to the control side was then calculated by convert-
ing the injured and uninjured areas into mm2 then converting to
volume by multiplying by 400 mm. To determine the levels of
microglial activation, brain tissue was stained using an anti-aMb2
integrin antibody (1:5,000, Bio-Rad, Kidlington, UK) and semi-
quantitative scores were allocated to each brain region (CTX, PYR,
HPP, STR, THAL, and EC) by an observer blinded to the treatment
of the groups, as previously described [51, 52], to describe micro-
glial appearance, that is, 0 (no activation), 1 (focal microglial acti-
vation), 2 (mild phagocytic activation affecting <50% of the
region), 3 (phagocytic activation affecting >50% of the region),
and 4 (total phagocytic activation). To determine levels of astro-
glial activation, sections were stained using an anti-glial ﬁbrillary
acidic protein (GFAP) antibody (1:6,000, Dako, Glostrup, Denmark)
before three 320 images per region of both the ipsilateral and
contralateral sides were captured. Images were then imported
into Image J which was used to obtain the mean and standard
deviation for the optical luminosity values (OLVs). The standard
deviation was subtracted from the values obtained for the sur-
rounding glass slide. Images were contrast stretched using Adobe
Photoshop 6.0.
Statistical Analysis
Statistical analysis was performed using SPSS. One-way analysis of
variance (ANOVA)s followed by Bonferroni’s multiple comparison
post-hoc test or Kruskal-Wallis nonparametric tests were used to
obtain p values where appropriate. p< .05 was signiﬁcant.
RESULTS
Validation of ES-MSC Identity
We modiﬁed the protocol published by Chen et al. [50] to differ-
entiate ESCs into ES-MSCs. To validate this protocol, we conﬁrmed
that the ES-MSCs had gained a characteristic MSC-like morphology
(Fig. 1Ai) along with the expression of the MSC markers CD105,
CD73, CD90 (Fig. 1Aii), and CD29 (Supporting Information Fig.
S1A), and lacked the expression of the hematopoietic markers
CD45 and CD14 (Supporting Information Fig. S1B, S1C). We also
conﬁrmed the loss of pluripotency marker expression (SOX2,
OCT4A, and NANOG) in these cells by RT-PCR (Fig. 1B).
ES-MSCs Have Enhanced Neuroprotective Potential in
Comparison to AF-MSCs
Various groups [44, 45, 53] have previously documented the
increased proliferative potential of PSC-MSCs in comparison to
BM-MSCs but we are the ﬁrst to compare PSC-MSCs to fetal
MSCs. We observed that ES-MSCs proliferate at an increased rate
in comparison to amniotic ﬂuid-derived MSCs (Fig. 1C).
Table 2. Quantitative (q)RT-PCR primers
Primer
target Forward sequence (50-30) Reverse sequence (50-30)
NF-jB1 TGCCAACAGATGGCCCATAC TGTTCTTTTCACTAGAGGCACCA
RelA GTGGGGACTACGACCTGAATG GGGGCACGATTGTCAAAGATG
IKK2 CTGGCCTTTGAGTGCATCAC CGCTAACAACAATGTCCACCT
b-ACTIN CGGGACCTGACTGACTACC TGAAGGTAGTTTCGTGGATGC
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Numerous groups have demonstrated the improved immu-
noregulatory potential of PSC-MSCs in comparison to the parental
population [11, 14, 53]. In support of these ﬁndings, we observed
that the media conditioned by ES-MSCs (ES-MSC-CM) had signiﬁ-
cantly higher anti-inﬂammatory potential than that derived from
AF-MSCs in an in vitro NF-jB reporter assay, using a lentiviral
reporter system previously described by us [49] (Fig. 1Di, 1Dii)).
Suppression of NF-jB activation in reporter cells by MSCs or their
CM or exosomes has been used by various other groups previ-
ously to demonstrate their anti-inﬂammatory potential [54–56].
Importantly, neither concentrated D10 medium alone or medium
conditioned by ESCs or iPSCs decreased NF-jB activation reporter
cells, thus conﬁrming that the effect is speciﬁc to MSC-CM (Sup-
porting Information Fig. S2A).
To determine whether the increased in vitro anti-
inﬂammatory potential of PSC-MSC-CM translates to an increased
therapeutic potential in vivo, we injected the cells into the contra-
lateral side of the brains of neonatal (postnatal day 7) mice sub-
jected to HI insult. Both AF-MSCs and ES-MSCs demonstrated the
ability to reduce forebrain tissue loss across all examined regions,
with the most notable decrease observed in the cortex, pyriform
cortex, striatum, and external capsule (Fig. 2Ai). In all examined
regions except the thalamus, ES-MSCs demonstrated a tendency
to reduce tissue loss to a higher degree than AF-MSCs reaching
signiﬁcance in the cortex, pyriform cortex, and overall (Fig. 2Ai).
Representative images of the three treated groups (PBS, AF-MSC,
and ES-MSC) are shown in Figure 2Aii. Both cell types also reduced
HI-induced microglial activation. The reduction achieved by ES-
MSC injection reached signiﬁcance in all examined regions and
overall whereas the reduction achieved by AF-MSC treatment
only reached signiﬁcance in the striatum (Fig. 2Bi). Notably,
ES-MSCs exhibited a tendency to reduce microglial activation to a
higher degree than AF-MSCs in all examined regions, reaching sig-
niﬁcance in the thalamus and overall (Fig. 2Bi). Representative
images of the levels of microglial activation in all three groups are
shown in Figure 2Bii. We observed that MSC injection was able to
prevent the transition of microglia from a ramiﬁed, inactive mor-
phology to the round, phagocytic phenotype observed in the PBS
control group (Fig. 2Biii).
A similar effect was observed for astroglial activation assessed
through GFAP immunoreactivity. We observed a trend toward
reduced levels of GFAP immunoreactivity in response to HI insult
in the MSC-treated groups in all examined regions of the forebrain
except the striatum, where only ES-MSCs decreased astroglial acti-
vation (Fig. 2Ci). Again, ES-MSCs showed a trend toward reducing
GFAP immunoreactivity to a higher degree than AF-MSCs, with
this difference reaching signiﬁcance in the striatum (Fig. 2Ci). No
signiﬁcant differences were observed between treatments in the
contralateral side (data not shown). We observed reduced overall
GFAP immunoreactivity in response to treatment with either type
of MSCs over the PBS control (Fig. 2Cii) and substantially reduced
and more punctate staining of GFAP1 astroglial processes in the
ES-MSC treatment group compared with the other two treatment
groups (PBS and AF-MSC) (Fig. 2Ciii).
ES-MSCs Exhibit Higher Levels of NF-jB Activation
than AF-MSCs
Since NF-jB activity has previously been linked to the therapeutic
potential of MSCs [28–30], we then determined whether the
increased anti-inﬂammatory potential of ES-MSCs compared with
AF-MSCs was due to increased NF-jB activation leading to
increased production of anti-inﬂammatory cytokines. We
Figure 1. ES-MSCs have increased anti-inﬂammatory potential compared with AF-MSCs. (Ai): Phase contrast images to show morphology of
ESCs, AF-MSCs, and ES-MSCs. 310 magniﬁcation. (Aii): Flow cytometry demonstrates the acquisition of MSC marker expression in ES-MSCs.
(B): RT-PCR shows loss of pluripotency-associated transcripts in ES-MSCs. (C): Graph to show the proliferation rate of ES-MSCs versus AF-MSCs.
(Di): Schematic of pLNT-NF-jB-Nluc and pLNT-SFFV-Vluc lentiviral constructs. (Dii): Anti-inﬂammatory assay demonstrates that ES-MSC-CM
decreases NF-jB activation in reporter cells to a higher degree than AF-MSC-CM. *, p< .05; **, p< .01. Abbreviations: AF-MSC, amniotic ﬂuid-
derived MSC; ESC, embryonic stem cell; ES-MSC, ESC-derived MSC; iMSC, iPSC-derived MSC; iPSC, induced pluripotent stem cell; MSC, mesen-
chymal stem cell; NF-jB, nuclear factor-kappa B; PSC-MSC, pluripotent stem cell-derived MSC; TNFa, tumor necrosis factor a.
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performed qRT-PCR for three NF-jB target genes, NF-jB1, IKK2,
and RelA, in MSCs under basal conditions and observed that the
levels of expression of these transcripts were higher in ES-MSCs
compared with AF-MSCs (Fig. 3A). Additionally, Western blotting
revealed an increase in IKK2 protein expression in ES-MSCs
compared with AF-MSCs (Fig. 3B) and the levels of NF-jB activa-
tion following TNFa stimulation of NF-jB reporter MSCs were also
higher in these cells, as assessed by a luciferase assay (Fig. 3C).
To show that these observations were not speciﬁc to the origin
of the MSCs we also demonstrated increased activation of NF-jB in
Figure 2. ES-MSCs have a greater neuroprotective potential than AF-MSCs following HI injury in the mouse brain. (Ai): Graph and
(Aii) phase contrast images to show ipsilateral brain tissue volume loss at 48 hours post-HI. Scale bar: 900 mm. (Bi): Graph, (Bii)
low magniﬁcation, and (Biii) high magniﬁcation phase contrast images to demonstrate the activation of Alpha M1 microglia. Scale
bars: 100 mm. (Ci): Graph, (Cii) low magniﬁcation and (Ciii) high magniﬁcation phase contrast images to show GFAP immunoreac-
tivity in the ipsilateral side of the brain at 48 hours post-HI. Scale bars: 100 mm. *, p< .05; **, p< .01; ***, p< .005; ***,
p< .001. Abbreviations: AF-MSC, amniotic ﬂuid-derived mesenchymal stem cell; ES-MSC, ESC-derived mesenchymal stem cell; OLV,
optical luminosity values.
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fetal BM-iMSCs comparedwith the parental fetal BM-MSC population
(Supporting Information Fig. S2B). BM-iMSC-CM also showed a tend-
ency toward having increased anti-inﬂammatory potential compared
with BM-MSC-CM (Supporting Information Fig. S2C).
ES-MSCs Secrete Increased Levels of anti-Inflammatory
Cytokines Compared with AF-MSCs
We then aimed to identify the anti-inﬂammatory cytokines, down-
stream of NF-jB, that contribute to the increased anti-
inﬂammatory potential of ES-MSC-CM compared with AF-MSC-
CM. A cytokine array identiﬁed increases in the production of IL-
13, IL-1ra and macrophage inhibitory factor (MIF) by ES-MSCs
compared with AF-MSCs (Fig. 3D). Since IL-13 and IL-1ra are NF-
jB target genes we investigated the secretion of these cytokines
further using ELISAs and conﬁrmed that both IL-13 and IL-1ra
were released at signiﬁcantly higher levels by ES-MSCs than AF-
MSCs (Fig. 3Ei, 3Eii).
NF-jB-Induced IL-13 Production Contributes to the
Increased anti-Inflammatory Potential of ES-MSCs
Compared with AF-MSCs
To determine whether elevated NF-jB activation causes increased
secretion of IL-13 and IL-1ra in MSCs, we used either TNFa stimu-
lation or overexpression of IKK2 to activate NF-jB signaling in AF-
MSCs. We validated the ability of the IKK2 expression plasmid to
increase NF-jB activation in AF-MSCs using a luciferase assay (Fig.
4Ai) and qRT-PCR for NF-jB target gene expression (Fig. 4Aii). We
then used an ELISA to determine whether NF-jB activation by
either TNFa stimulation or overexpression of IKK2 causes
increased IL-13 or IL-1ra production.We found that increasing NF-
jB activation by either of these methods led to increased levels of
IL-13, but not IL-1ra, production in AF-MSCs (Fig. 4Bi, 4Bii).
Finally, to determine whether NF-jB-induced IL-13 production
contributes to the increased anti-inﬂammatory potential of ES-
MSCs compared with AF-MSCs we blocked IL-13 production in
ES-MSCs using an inhibitory peptide (IL-13P). Treatment with the
IL-13P resulted in the decreased anti-inﬂammatory potential of
PSC-MSC-CM (Fig. 4C) thus indicating that, as predicted, NF-jB-
stimulated IL-13 production contributes to the increased anti-
inﬂammatory potential of ES-MSCs compared with AF-MSCs. A
schematic for the proposed link between NF-jB activation and IL-
13 production in PSC-MSCs versus other types of MSCs is shown
in the graphical abstract.
NF-jB-Stimulated IL-13 Production Also Contributes to
the Increased Anti-Inflammatory Potential of iMSC-CM
Over AF-MSC-CM
We then wanted to determine whether the above ﬁndings were
also true for the other type of PSC-MSCs, iMSCs. We ﬁrst reprog-
rammed amniotic ﬂuid-derived (AF)-MSCs into iPSCs and con-
ﬁrmed the reactivation of the expression of pluripotency markers
(Supporting Information Fig. S3A) and their expression of early lin-
eage markers upon embryoid body differentiation (Supporting
Information Fig. S3B). We then generated iMSCs using the same
protocol used to derive ES-MSCs and validated their MSC-like
morphology (Supporting Information Fig. S4Ai), cell surface
marker expression proﬁle (Supporting Information Fig. S1, S4Aii),
and their loss of pluripotency marker expression (Supporting Infor-
mation Fig. S4B).
Interestingly, similar to ES-MSCs, iMSCs exhibited an increased
proliferation rate in comparison to AF-MSCs (Supporting Informa-
tion Fig. S4C). Moreover, iMSC-CM exhibited increased anti-
inﬂammatory potential (Fig. 5A), which was concomitant with
increased NF-jB activation (Fig. 5Bi–5Biii) and increased production
Figure 3. ES-MSCs exhibit increased NF-jB activation and anti-inﬂammatory cytokine production. (A): qPCR to show NF-jB target gene
expression in ES-MSCs. (B): Western blot to show IKK2 protein expression in AF-MSCs and ES-MSCs. (C): Luciferase assay to show NF-jB acti-
vation in AF-MSCs and ES-MSCs in response to TNFa. (D): Cytokine array to show levels of anti-inﬂammatory cytokines in ES-MSC-CM versus
AF-MSC-CM. (E): ELISA to show levels of (Ei) IL-13 and (Eii) IL-1ra production by ES-MSCs and AF-MSCs. *, p< 0.05; **, p< .01; ***, p< .005.
Abbreviations: AF-MSC, amniotic ﬂuid-derived mesenchymal stem cell; ES-MSC, ESC-derived mesenchymal stem cell; CM, conditioned
medium; TNFa, tumor necrosis factor a.
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of anti-inﬂammatory cytokines (Fig. 5Ci–5Ciii). Finally, we demon-
strated that increased IL-13 production contributes to the increased
anti-inﬂammatory potential of iMSC-CM over AF-MSC-CM by show-
ing that an IL-13 inhibitory peptide signiﬁcantly reduced the
ability of iMSC-CM to reduce NF-jB activation in reporter cells
(Fig. 5D).
DISCUSSION
To our knowledge, this is the ﬁrst direct comparison of the thera-
peutic potential of PSC-MSCs and primary fetal MSCs. PSC-MSCs
have been shown to have superior immunomodulatory properties
to adult MSCs [43, 53]; however, we hypothesized that fetal MSCs
may be comparable to PSC-MSCs due to their more primitive ori-
gin. Here we show that, contrary to our hypothesis, PSC-MSCs
proliferate faster than AF-MSCs and have greater anti-
inﬂammatory potential than both fetal BM-MSCs and AF-MSCs.
These results suggest that PSC-MSCs are the optimal cell source
for therapeutic use, even over our current “gold standard,” fetal
MSCs. The use of PSC-MSCs would bypass the challenge of replica-
tive senescence, since pluripotent cells can self-renew indeﬁnitely
in culture, and using the same cell source for multiple therapies
would allow a level of standardization that would not be possible
with other sources of MSCs.
As mentioned, PSC-MSCs have superior therapeutic capacity
in a wide variety of disease contexts, yet we lack understanding of
the molecular mechanisms underlying this phenomenon and of
MSC therapeutic mechanisms more generally. Here we show that
PSC-MSCs exhibit increased NF-jB activation in comparison to AF-
MSCs and that this occurs concomitantly with increased IL-13 pro-
duction and anti-inﬂammatory capacity, providing for the ﬁrst
time a potential explanation for the increased therapeutic poten-
tial of PSC-MSCs over other sources of MSCs.
Moreover, we demonstrate the ﬁrst comparison of the two
different PSC-MSC types, iMSCs and ES-MSCs.We and others [57]
show that iMSCs exhibit decreased levels of MSC marker expres-
sion in comparison to ES-MSCs and AF-MSCs and that iMSCs are a
Figure 4. NF-jB-induced IL-13 production contributes to the increased anti-inﬂammatory potential of ES-MSC-CM compared with AF-MSC-CM.
(A): Validation of IKK2 activation of NF-jB by (Ai) luminometry and (Aii) qRT-PCR. (B): ELISA to show that NF-jB activation by (Bi) TNFa stimula-
tion and (Bii) IKK2 overexpression causes increased IL-13 but not IL-1ra production. (C): Luciferase assay to show that IL-13 blockade decreases
the anti-inﬂammatory potential of ES-MSC-CM. IKK: inhibitor of jB kinase. *, p< .05, **, p< .01; ***, p< .005. Abbreviations: AF-MSC, amniotic
ﬂuid-derived mesenchymal stem cell; CM, conditioned medium; ES-MSC, ESC-derived mesenchymal stem cell; TNFa, tumor necrosis factor a.
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more heterogenous population generally. We have also observed
that ES-MSCs have similar size and granularity to AF-MSCs than
iMSCs do and that ES-MSCs release higher levels of the anti-
inﬂammatory cytokines IL-10 and EGF and lower levels of the pro-
inﬂammatory cytokine IL-6 in comparison to iMSCs (data not
shown), suggesting that ES-MSCs are the most appropriate for
therapeutic use. Despite this, iMSCs present the advantages of
being able to be used autologously, or to be patented, which are
not possible in the case of ES-MSCs.
Our study also shows that ﬁrst trimester AF-MSCs have neuro-
protective potential following HI injury in the mouse brain. Our HI
model mimics prenatal brain injury that can lead to lifelong cogni-
tive disabilities such as cerebral palsy and epilepsy, and the ability
of MSCs to prevent this. Our results ﬁt with previous ﬁndings that
demonstrate the ability of BM-MSCs and multipotent adult pro-
genitor cells (MAPCs) to exert neuroprotective effects after HI in
rodent and larger animal models [58–63]. Moreover, we show for
the ﬁrst time that ES-MSCs exhibit greater neuroprotective poten-
tial than AF-MSCs in this context.
NF-jB-stimulated IL-13 production may be one of many ways
in which MSCs protect the brain after HI injury. For example, NF-jB
is also likely to stimulate the production of additional protective
cytokines and small molecules such as IL-10, PGE2, and IDO either
directly or in combination with other factors; we have observed the
increased production of IL-10 by ES-MSCs in comparison to AF-
MSCs (data not shown). In addition, we and others [42] show that
ES-MSCs express lower levels of IL-6 in comparison to other MSC
types, which may contribute to their increased therapeutic effects
since IL-6 generally acts as a pro-inﬂammatory cytokine. We also
identify IL-1ra and MIF as cytokines that are produced at higher lev-
els by PSC-MSCs than AF-MSCs. Zhang et al. [11] have previously
shown that MIF (and growth/differentiation factor 15) production
Figure 5. NF-jB-induced IL-13 production contributes to the increased anti-inﬂammatory potential of iMSC-CM compared with AF-MSC-
CM. (A): Anti-inﬂammatory assay demonstrates that iMSC-CM decreases NF-jB activation in reporter cells to a higher degree than AF-MSC-
CM. (Bi): Western blot to show IKK2 protein expression in AF-MSCs and iMSCs. (Bii): qPCR to show increased NF-jB activation in iMSCs com-
pared with AF-MSCs. (Biii): Luciferase assay to show NF-jB activation in AF-MSCs and iMSCs in response to TNFa. (Ci): Cytokine array to
show levels of anti-inﬂammatory cytokines in iMSC-CM versus AF-MSC-CM. (Cii): ELISA to show levels of IL-13 and (Ciii) IL-1ra produced by
iMSCs and AF-MSCs. (D): Luciferase assay to show that IL-13 blockade decreases the anti-inﬂammatory potential of iMSC-CM. *, p< .05; **,
p <.01; ***, p< .005. Abbreviations: AF-MSC, amniotic ﬂuid-derived mesenchymal stem cell; CM, conditioned medium; ES-MSC, ESC-derived
mesenchymal stem cell; iMSCs, induced pluripotent stem cell-derived MSCs; NF-jB, nuclear factor-kappa B; TNFa, tumor necrosis factor a.
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plays a role in the increased cardioprotective role of iMSC-CM over
BM-MSC-CM and IL-1ra has been shown to be important for the
therapeutic effects of MSCs in the lung [64]. Lian et al. [44] also
demonstrated increased production of stromal cell-derived factor
(SDF)1a, stem cell factor (SCF) and ﬁbroblast growth factor (FGF)2
in iMSCs compared with the parental cell population. It is likely that
these cytokines are context-dependent and that cocktails of factors,
rather than one individual factor, are important since the outcomes
from early clinical trials with single cytokines for brain and cardio-
vascular diseases has failed to meet expectations [63, 64]. One
potential challenge is the lack of stability of growth factors, which
could potentially be addressed by the use of extracellular vesicles
[12, 13, 15].
CONCLUSION
By illuminating the molecular mechanisms underlying the
improved therapeutic potential of PSC-MSCs, and therefore of
MSCs more generally, our work may have implications for improv-
ing the efﬁciency of MSC therapies. For example, NF-jB signaling
could be manipulated in MSCs using a lentiviral IKK2 overexpres-
sion plasmid to improve the therapeutic potential of the extracel-
lular vesicles released by MSCs. The anti-inﬂammatory properties
of PSC-MSCs are clearly superior not only to adult MSCs but also
to fetal MSCs and it is, therefore, likely that they represent the
most promising source for therapeutic use in the future, so long
as their long-term stability is proven and risks of teratoma forma-
tion are circumvented.
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